Tokai Pharmaceuticals
Pharmaceutical company that developed therapies for prostate cancer, focusing on androgen receptor pathway modulation. Merged with Novus Therapeutics in 2017.
Notes
Tokai Pharmaceuticals was a pharmaceutical company focused on developing therapies for prostate cancer. The company was headquartered in Cambridge, Massachusetts.
Tokai developed galeterone (TOK-001), an oral small molecule that was designed to block the androgen receptor pathway through multiple mechanisms, including CYP17 lyase inhibition and androgen receptor degradation. The drug was being developed for castration-resistant prostate cancer.
The company was part of the Apple Tree Partners portfolio.
Merged with Novus Therapeutics in 2017 in a reverse merger transaction. The combined company continued as Novus Therapeutics.
Team
- Historical leadership (company merged in 2017)
Additional Research Findings
- Apple Tree Partners portfolio company
- Prostate cancer focus
- Galeterone (TOK-001) lead program
- Androgen receptor pathway modulation
- Cambridge, Massachusetts headquarters
- Founded in 2004
- Merged with Novus Therapeutics in 2017
Sources
- Apple Tree Partners Portfolio
- Business Wire merger announcements
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Apple Tree Partners | New York, USA | biotech-focused | series-aseries-b+2 | 23 |